17 research outputs found
Cytolytic Virus Activation Therapy for Epstein-Barr virus associated nasopharyngeal and gastric carcinoma
Cytolytic Virus Activation Therapy for Epstein-Barr virus associated nasopharyngeal and gastric carcinoma
Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease
Genetics of disease, diagnosis and treatmen
The role of phospholipase D in modulating the MTOR signaling pathway in polycystic kidney disease
The mammalian target of rapamycin (mTOR) signaling pathway is aberrantly activated in polycystic kidney disease (PKD). Emerging evidence suggests that phospholipase D (PLD) and its product phosphatidic acid (PA) regulate mTOR activity. In this study, we assessed in vitro the regulatory function of PLD and PA on the mTOR signaling pathway in PKD. We found that the basal level of PLD activity was elevated in PKD cells. Targeting PLD by small molecule inhibitors reduced cell proliferation and blocked mTOR signaling, whereas exogenous PA stimulated mTOR signaling and abolished the inhibitory effect of PLD on PKD cell proliferation. We also show that blocking PLD activity enhanced the sensitivity of PKD cells to rapamycin and that combining PLD inhibitors and rapamycin synergistically inhibited PKD cell proliferation. Furthermore, we demonstrate that targeting mTOR did not induce autophagy, whereas targeting PLD induced autophagosome formation. Taken together, our findings suggest that deregulated mTOR pathway activation is mediated partly by increased PLD signaling in PKD cells. Targeting PLD isoforms with pharmacological inhibitors may represent a new therapeutic strategy in PKD